{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:24:02Z","timestamp":1777497842795,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,28]]},"DOI":"10.7759\/cureus.78122","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:56:28Z","timestamp":1738065388000},"source":"Crossref","is-referenced-by-count":2,"title":["Biological Agents\u2019 Adverse Events in Jordanian Childhood Rheumatic Diseases: A Single-Center Experience"],"prefix":"10.7759","author":[{"given":"Motasem O","family":"Alsuweiti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heba Q","family":"Alma\u2019aitah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza M","family":"Alnsour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra A","family":"Alwraikat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali I","family":"Alzyoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Nobani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raed M","family":"Alzyoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041810","article-title":"Leflunomide or methotrexate for juvenile rheumatoid arthritis","volume":"352","author":"Silverman E","year":"2005","unstructured":"Silverman E, Mouy R, Spiegel L, et al.. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005, 352:1655-66. 10.1056\/NEJMoa041810","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0031-3955(16)40055-6","article-title":"Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future","volume":"42","author":"Giannini EH","year":"1995","unstructured":"Giannini EH, Cawkwell GD. Drug treatment in children with juvenile rheumatoid arthritis. Past, present, and future. Pediatr Clin North Am. 1995, 42:1099-125. 10.1016\/s0031-3955(16)40055-6","journal-title":"Pediatr Clin North Am"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.08.003","article-title":"Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database","volume":"86","author":"Cabrera N","year":"2019","unstructured":"Cabrera N, Lega JC, Kassai B, et al.. Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database. Joint Bone Spine. 2019, 86:343-50. 10.1016\/j.jbspin.2018.08.003","journal-title":"Joint Bone Spine"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12365","article-title":"Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety","volume":"19","author":"Al-Mayouf SM","year":"2016","unstructured":"Al-Mayouf SM, Alenazi A, AlJasser H. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety. Int J Rheum Dis. 2016, 19:600-5. 10.1111\/1756-185X.12365","journal-title":"Int J Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2021.7953","article-title":"Biologics in juvenile idiopathic arthritis-main advantages and major challenges: a narrative review","volume":"36","author":"Adrovic A","year":"2021","unstructured":"Adrovic A, Yildiz M, K\u00f6ker O, \u015eahin S, Barut K, Kasap\u00e7opur \u00d6. Biologics in juvenile idiopathic arthritis-main advantages and major challenges: a narrative review. Arch Rheumatol. 2021, 36:146-57. 10.46497\/ArchRheumatol.2021.7953","journal-title":"Arch Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-010-1238-z","article-title":"Biologics in children's autoimmune disorders: efficacy and safety","volume":"170","author":"Breda L","year":"2011","unstructured":"Breda L, Del Torto M, De Sanctis S, Chiarelli F. Biologics in children's autoimmune disorders: efficacy and safety. Eur J Pediatr. 2011, 170:157-67. 10.1007\/s00431-010-1238-z","journal-title":"Eur J Pediatr"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087130","article-title":"Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis","volume":"68","author":"Tynj\u00e4l\u00e4 P","year":"2009","unstructured":"Tynj\u00e4l\u00e4 P, V\u00e4h\u00e4salo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis. 2009, 68:552-7. 10.1136\/ard.2007.087130","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200437","article-title":"Biologic switching among nonsystemic juvenile idiopathic arthritis patients: a cohort study in the Childhood Arthritis and Rheumatology Research Alliance Registry","volume":"48","author":"Mannion ML","year":"2021","unstructured":"Mannion ML, Xie F, Horton DB, Ringold S, Correll CK, Dennos A, Beukelman T. Biologic switching among nonsystemic juvenile idiopathic arthritis patients: a cohort study in the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol. 2021, 48:1322-9. 10.3899\/jrheum.200437","journal-title":"J Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"Gerloni V","year":"2008","unstructured":"Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis. 2008, 67:1145-52. 10.1136\/ard.2007.069484","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5152\/TurkArchPediatr.2024.23221","article-title":"How safe are biological agents in pediatric rheumatology?","volume":"59","author":"Nur Sunar Yayla E","year":"2024","unstructured":"Nur Sunar Yayla E, Y\u0131ld\u0131z \u00c7, Esmeray \u015eenol P, Kara\u00e7ay\u0131r N, Gezgin Y\u0131ld\u0131r\u0131m D, Bakkalo\u011flu SA. How safe are biological agents in pediatric rheumatology?. Turk Arch Pediatr. 2024, 59:185-92. 10.5152\/TurkArchPediatr.2024.23221","journal-title":"Turk Arch Pediatr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2020.102001","article-title":"Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a single center in Turkey","volume":"58","author":"Balc\u0131 S","year":"2020","unstructured":"Balc\u0131 S, Demir \u0130, Serbes M, Do\u011fruel D, Alt\u0131nta\u015f DU, Ekinci RM. Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a single center in Turkey. Reumatologia. 2020, 58:367-74. 10.5114\/reum.2020.102001","journal-title":"Reumatologia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22961","article-title":"Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German Biologics in Pediatric Rheumatology Registry","volume":"69","author":"Becker I","year":"2017","unstructured":"Becker I, Horneff G. Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German Biologics in Pediatric Rheumatology Registry. Arthritis Care Res (Hoboken). 2017, 69:552-60. 10.1002\/acr.22961","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1109-8","article-title":"The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis","volume":"18","author":"Beukelman T","year":"2016","unstructured":"Beukelman T, Xie F, Baddley JW, et al.. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther. 2016, 18:210. 10.1186\/s13075-016-1109-8","journal-title":"Arthritis Res Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1780-z","article-title":"Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries","volume":"20","author":"Swart J","year":"2018","unstructured":"Swart J, Giancane G, Horneff G, et al.. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018, 20:285. 10.1186\/s13075-018-1780-z","journal-title":"Arthritis Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-019-04498-z","article-title":"Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center","volume":"40","author":"Ko\u00e7 R","year":"2020","unstructured":"Ko\u00e7 R, S\u00f6nmez HE, \u00c7akan M, Karada\u011f \u015eG, Tanatar A, \u00c7akmak F, Aktay Ayaz N. Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center. Rheumatol Int. 2020, 40:771-6. 10.1007\/s00296-019-04498-z","journal-title":"Rheumatol Int"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration","volume":"62","author":"Diak P","year":"2010","unstructured":"Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010, 62:2517-24. 10.1002\/art.27511","journal-title":"Arthritis Rheum"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212613","article-title":"Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors","volume":"77","author":"Beukelman T","year":"2018","unstructured":"Beukelman T, Xie F, Chen L, et al.. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. Ann Rheum Dis. 2018, 77:1012-6. 10.1136\/annrheumdis-2017-212613","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/334438-biological-agents-adverse-events-in-jordanian-childhood-rheumatic-diseases-a-single-center-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T11:56:30Z","timestamp":1738065390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/334438-biological-agents-adverse-events-in-jordanian-childhood-rheumatic-diseases-a-single-center-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.78122","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,28]]}}}